Not independent
Tenure on this board
1.1 yrs
Meeting calendar
PRME · Special meeting · Friday, August 1, 2025
Prime Medicine Inc
10 nominees · 2 ballot items.
Two proposals are on the ballot: Proposal 1 — Approval of repricing of certain outstanding stock options under the 2019 Plan and/or the 2022 Plan; Proposal 2 — Approval of an adjournment of the Special Meeting to permit further solicitation if needed.
Market cap
$703M
1Y TSR
+81.2%
Board grade
D
Record date
Jul 9, 2025
Filing
DEF 14A
Meeting concluded · Aug 1, 2025
Follow how the vote landed and what changed on Prime Medicine Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Approval of repricing of certain outstanding stock options
ManagementBoard: FOROne-time repricing of eligible underwater stock options granted under the 2019 Stock Option and Grant Plan and the 2022 Stock Option and Incentive Plan to reduce exercise prices to a specified Repriced Exercise Price, with retention dates, conditions for early reversion to Original Price, and related effects on vesting, accounting, and potential consequences if the stock price remains underwater.
- 2
Approval of an adjournment of the Special Meeting
ManagementBoard: FORIf there are insufficient votes for Proposal 1 at the time of the Special Meeting or if a quorum is not present, the Company seeks to adjourn the Special Meeting to a later date to allow for additional solicitation of proxies in favor of Proposal 1.
Director elections
Nominees on the ballot10
Jeremy Duffield, M.D. Ph.D., FRCP
Not independent
Tenure on this board
New nominee
Not independent
Tenure on this board
4.9 yrs
Also a director at
Septerna Inc (SEPN)
Independent
Tenure on this board
4.7 yrs
Independent
Tenure on this board
4.7 yrs
Also a director at
Rallybio Corp (RLYB)
Independent
Tenure on this board
4.6 yrs
Also a director at
Agios Pharmaceuticals Inc (AGIO)
Independent
Tenure on this board
4.7 yrs
Also a director at
Neogenomics Inc (NEO)Dmc Global Inc (BOOM)
Independent
Tenure on this board
3.1 yrs
Not independent
Tenure on this board
5.8 yrs
Also a director at
Vir Biotechnology Inc (VIR)Sana Biotechnology Inc (SANA)
Independent
Tenure on this board
6.8 yrs
Also a director at
Denali Therapeutics Inc (DNLI)Regeneron Pharmaceuticals Inc (REGN)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Alphabet Inc. | 9.2% | 16,562,498 | $58M |
| 2 | STATE STREET CORP | 3.5% | 6,345,125 | $22M |
| 3 | ARK Investment Management LLC | 3.5% | 6,246,827 | $22M |
| 4 | T. Rowe Price Investment Management, Inc. | 3.0% | 5,481,893 | $19M |
| 5 | BlackRock, Inc. | 2.6% | 4,679,241 | $16M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 4,474,162 | $16M |
| 7 | BALYASNY ASSET MANAGEMENT L.P. | 2.3% | 4,123,365 | $14M |
| 8 | Casdin Capital, LLC | 1.8% | 3,167,175 | $11M |
| 9 | BlackRock, Inc. | 1.7% | 3,016,314 | $10M |
| 10 | Woodline Partners LP | 1.7% | 3,003,313 | $10M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Prime Medicine Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Trubridge IncTBRG
Special meeting·Jul 7, 2026·$393M
Reference
Frequently asked questions
- When is the Prime Medicine Inc 2025 special meeting?
- Prime Medicine Inc (PRME) holds its 2025 special shareholder meeting on Friday, August 1, 2025.
- What is the record date for the Prime Medicine Inc 2025 meeting?
- The record date for the Prime Medicine Inc 2025 meeting is Wednesday, July 9, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Prime Medicine Inc's 2025 meeting?
- The board is presenting 10 director nominees at the Prime Medicine Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Prime Medicine Inc 2025 meeting?
- Shareholders will vote on 2 proposals at the Prime Medicine Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.